Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Oncimmune "relaunch" already delivering results

Oncimmune Holdings PLC

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone speaks to Thomas Warner from Proactive London about what he describes as the relaunch of the business. Gouldstone discusses the significant changes made to the company's strategy following his appointment in August, saying that his primary focus has been on maximising the commercial and scientific value of the company's Immune Insights platform, centred in their Dortmund labs. The new strategy, announced on October 12th, aims to expand the platform's capabilities in drug discovery and development and reach different customer verticals, extending from big pharma to smaller biopharma and CRO partnerships. With extensive industry experience dating back to 1990, including roles in major CROs and corporate finance, Gouldstone brings a wealth of expertise to Oncimmune. Since taking the helm, he has conducted a comprehensive review of the business, covering everything from finances to operations. The outcome has been positive, with a productive team in Germany, established relationships with large pharma, and a growing commercial team. Gouldstone's short tenure has already seen tangible successes, including the signing of four deals aligned with the new strategy, indicating early commercial traction. He anticipates continued growth and success in line with the company's evolving strategy and robust pipeline. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 05, 2023 12:00 PM Eastern Standard Time

Video

PathAI Announces Research Presentations at the San Antonio Breast Cancer Symposium

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced it will present four research presentations underscoring the value and potential of PathExplore’s* human interpretable features (HIFs), and one research presentation demonstrating the ability of the AIM-HER2* product to accurately predict HER2 scores, including in HER2-low cases, at the San Antonio Breast Cancer Symposium on December 5-9, 2023, in San Antonio, TX. “This research builds on our past successes and proceeds to show that PathAI’s algorithms continue to further our understanding of cancer biology and disease mechanisms,” said Andy Beck, M.D., Ph.D., co-founder and chief executive officer of PathAI. “At PathAI, we continue to demonstrate the clinical potential for these AI pathology tools, and we’re confident that it will ultimately translate to advancements in precision medicine and patient outcomes.” Poster #PO1-07-01: Artificial Intelligence-based prediction of Oncotype DX score from whole slide images using human-interpretable features and breast biomarkers The Oncotype DX Breast Recurrence Score assay (ODX) is a commonly used genomic test for patients with estrogen receptor (ER)-positive, HER2-negative, early-stage invasive breast cancer. While ODX predicts patients’ recurrence risk and benefit from chemotherapy, it is time-consuming and expensive. Using human-interpretable features extracted from H&E whole slide images with the PathExplore Breast model, together with manually assessed ER, PR, HER-2 scores, and tumor stage, PathAI, in collaboration with researchers from the Cleveland Clinic Foundation, developed interpretable models for predicting ODX recurrence scores using histological features and clinical covariates. The models achieved a level of performance comparable to previous deep-learning approaches, while also revealing the contribution of features such as cancer cell density, immune cell density, and variations in cancer nuclear shape and color to the ODX score prediction. Using readily available information, the model has the potential to be a convenient screening tool for patient stratification, which may lead to better patient care, lower costs, and faster treatment. Presenting Author: Nhat Le Time/Location: Wednesday, December 6, 12:00 PM – 2:00 PM, Poster Session 1 Poster #PO3-07-04: Prediction of PAM50 molecular subtypes from H&E-stained breast cancer specimens using tumor microenvironment features and additive multiple instance learning models PAM50, a 50-gene signature, classifies breast cancers into one of five subtypes and has emerged as a key prognostic indicator influencing treatment decisions. There is growing interest in bridging the gap between expression-based metrics and histopathology. In this poster, PathAI describes a computer vision-based approach to predict PAM50 classification using H&E-stained whole slide images (WSIs). Two separate machine learning approaches were developed to predict PAM50 subtypes from WSIs. Both models performed well in predicting Basal, Luminal A, Luminal B, and Luminal (A+B) subtypes, and provide biological interpretability not found in typical black-box models. The results support the notion that AI-powered digital pathology can accurately and reproducibly perform molecular-based classification tasks such as predicting PAM50 classifications using WSIs, suggesting a more efficient path toward clinically relevant breast cancer characterization. Presenting Author: Nhat Le Time/Location: Thursday, December 7, 12:00 PM – 2:00 PM CT, Poster Session 3 Poster #PO1-15-01: Digital pathology models reveal case-specific characteristics of the tumor microenvironment Tumor microenvironments are complex three-dimensional structures, but often only single histological sections are used to glean biological information for research purposes or in some diagnostic practices. These conclusions can also be affected by technical factors in slide preparation and digitization. In this research, PathAI applied PathExplore, a suite of digital pathology models to identify cell and tissue substances as well as their spatial relationships, to whole-slide images of breast cancer tumors and quantified intra- and inter-tumor heterogeneity in human-interpretable features of the tumor microenvironment. The results reveal biological and technical variability that can inform selection and interpretation of biomarkers derived from single slides. The ability to uniquely identify slides from the same case additionally demonstrates the technical robustness of digital pathology models for yielding quantitative insights into tumor biology. Presenting Author: Ylaine Gerardin Time/Location: Wednesday, December 6, 12:00 PM – 2:00 PM, Poster Session 1 Poster #PO2-14-12: Accurate quantification of slide-level HER2 scores in breast cancer using a machine-learning model, AIM-HER2 Breast Cancer The HER2 biomarker is critical in determining a breast cancer treatment course. To aid accurate interpretation of HER2-stained breast cancer specimens, PathAI developed the AIM-HER2 machine learning model, which demonstrates that the model performs comparably to pathologists in the prediction of HER2 scores (0-3+), including HER2-low. Comparable concordance between AIM-HER2 and pathologists was also observed irrespective of the HER2 antibody clone or slide scanner used. AIM-HER2 was developed using “Additive Multiple Instance Learning,” a novel technique which yields highly explainable results as slide-level scores and heatmaps, thereby supporting future use in AI-assisted pathologist workflows. Presenting Author: John Shamshoian Time/location: Wednesday, December 6, 5:00 – 7:00 PM CT, Poster Session 2 For more information, visit our poster sessions. For BioPharma opportunities, reach out to meet with our team at bd@pathai.com. To get in touch with our Digital Diagnostics team, reach out to digitaldx@pathai.com. For Academic Research opportunities, reach out to ryan.leung@pathai.com and liz.thomas@pathai.com *PathExplore and AIM-HER2 are For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is a recognized leader in the biopharma partnering space, uniquely combining AI-powered pathology solutions with end-to-end central pathology and histology services. The company supports biopharma partners in executing clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to successfully gauging therapeutic efficacy, accelerating drug development for complex diseases. PathAI has already supported multiple Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials, and is now expanding into larger scale global Phase 3 studies, as well as additional indications. PathAI provides a fully integrated approach to clinical trials, enabling pharma partners to leverage the power of AI without the heavy lift of implementation. This helps reduce the impact of challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. The lab offers all major immunohistochemistry staining platforms, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner, plus seamless integration of PathAI's advanced AI-solutions to ensure high-quality, reproducible results with every scan. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

December 05, 2023 12:00 PM Eastern Standard Time

Image

Intelligent Health 2023 Global Summit Features Keynote by AI Luminary Tom Lawry

1BusinessWorld

The Intelligent Health 2023 Global Summit, a cornerstone event for healthcare innovation, is proud to announce a must-attend session, “The Intelligent Health Revolution is Upon Us. Are You Ready?” featuring Tom Lawry, the Managing Director of Second Century Tech. Scheduled for December 11, 2023, from 1:00 pm to 1:30 pm, this virtual event promises to be a beacon of knowledge for healthcare professionals, technologists, and innovators worldwide. https://1businessworld.com/2023-intelligent-health-summit/ Tom Lawry, a globally recognized AI keynote speaker and a transformative advisor in health and medical fields, will lead the session. Lawry's extensive career includes notable roles such as National Director for AI for Health and Life Sciences and Director of Worldwide Health at Microsoft. He is also the acclaimed author of “Hacking Healthcare – How AI and the Intelligent Health Revolution Will Reboot an Ailing System.” His thought leadership has been featured in prestigious publications like Forbes, CEO Magazine, and Harvard Business Review. The session will delve into the burgeoning Intelligent Health Revolution, with a focus on the integration and profound impact of AI in healthcare. Lawry will share his invaluable insights on how AI is reshaping healthcare delivery, enhancing patient engagement, and boosting system efficiency. He will also discuss adaptive strategies for healthcare organizations in this rapidly evolving technological landscape. Tom Lawry’s unique blend of expertise and experience positions him as a visionary voice at the intersection of technology and healthcare. Attendees will benefit from his perspectives, shaped by his roles as a health system executive and board member. This session is a rare opportunity for attendees to engage with one of the most influential voices in healthcare technology, as recognized by a Harris Poll of attendees at the 2023 JP Morgan Healthcare Conference. The Intelligent Health 2023 Global Summit, produced by the Intelligent Health Association and powered by 1BusinessWorld, is dedicated to exploring the future of healthcare. This session with Tom Lawry is a testament to the summit’s commitment to bringing the forefront of healthcare innovation to a global audience. We invite healthcare professionals, technologists, and anyone interested in the future of health and AI to join this enlightening session. Register now to secure your virtual seat and be part of the Intelligent Health Revolution. https://1businessworld.com/2023-intelligent-health-summit/ All news and content distribution in partnership with News Direct. About the Intelligent Health Association: The Intelligent Health Association (IHA) is a global consortium of healthcare and technology leaders committed to advancing digital healthcare. Our goal is to disseminate unbiased information on innovative technologies that enhance patient care and improve clinical and business processes. The IHA champions the transformation of healthcare through high-quality educational programs and networking events, facilitating the adoption and implementation of new technologies in health and wellness ecosystems. We are dedicated to reshaping healthcare through innovation and leadership, ensuring a future where technology seamlessly integrates with patient care. Intelligent Health Association About 1BusinessWorld: 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

December 05, 2023 10:54 AM Eastern Standard Time

Image

Introducing Sulinu

Sulinu

Sulinu, the trailblazing company transforming the approach to pre- and post-operative nutritional care, announces its official launch. Established by the highly regarded Clinical Dietitian, Kylie Bensley MS, RD, Sulinu introduces a paradigm shift with her comprehensive nutrition programs incorporating clinically-proven ingredients to enhance preparation for and recovery from elective procedures. As the first company of its kind, Sulinu is poised to make a profound impact on the cosmetic surgery industry, setting new standards for patient care and outcomes. Boasting over a decade of experience as a distinguished expert in nutrition, Bensley has dedicated her career to working with esteemed hospital post-surgical facilities in Cambridge and Boston, MA. Through this experience, she observed the challenges hindering proper healing and the consequent damage to the body resulting from insufficient nutrients for optimal repair. What makes Sulinu truly groundbreaking and a category innovator is that has created: The inaugural and most complete surgical recovery powder on the market and the ONLY medical-grade one available to consumers An All-IN-ONE powder that delivers vital bioavailable ingredients to the bloodstream for optimal recovery, including proteins, collagen, vitamins, enzymes, minerals and amino acids. A cleaner and more wholesome alternative to the enteral and oral nutritional supplements utilized in leading surgical facilities The ONLY powder of its kind to completely dissolve in liquid A once-daily, superblend scoop delivers immune-boosting, mind-calming and incision-healing properties for optimal nutrition and recovery Sulinu stands at the forefront of innovations in cosmetic surgery nutrition, ensuring that individuals can now navigate their surgical journeys with enhanced support and optimal well-being. By pioneering a program that underscores the importance of gut health in incision healing, Bensley simplifies and streamlines the dietary process for the body to bolster immunity, minimize swelling, alleviate bruising and fill nutrient gaps. "Nutrition is a fundamental yet often overlooked aspect of the cosmetic surgery journey,” says Bensley. “Sulinu was born out of the belief that individuals deserve inclusive, expert-guided nutrition plans to optimize their surgical experience, from preparation to recovery." The Sulinu program is designed with three key components that work collectively to combat the factors known to impair incision healing, increase infection risk, and delay overall downtime. 1. Before + After Vitals Dietary Powder Supplement*: An all-in-one gluten-free powder formulated with patented ingredients to deliver the essential and crucial nutrients needed before and after surgery. Bioenhanced Vitamin C – clinically proven to reduce inflammation and help grow and repair body tissue Proteolytic Enzymes - helps absorb protein and reduce the amount that’s excreted when combined with other proteins, increasing the absorption of total serum amino acids, which are essential for incision healing Hydrolyzed Collagen - stimulates skin cells to produce more collagen, essential to giving skin structure, strength and elasticity Biome Synbiotics – blend of both patented prebiotics and patented probiotics clinically proven to survive stomach acids and arrive alive in the gut to support a healthy microbiome. 2. Pre-Op Meal Guide. This extensive guide not only prepares the body to fast-track beautiful results, it also helps navigate dietary pitfalls that can contribute to experiencing dangerous complications. All recipes are carefully curated with ingredients that work together to turbocharge healing in efforts to avoid excessive bruising, swelling and slow-to-mend incisions. 3. Comprehensive 2-Week Post-Op Meal Plan. Tailored to specific cosmetic procedures (tummy, face, breast), each delicious, nutrient-rich, high-protein recipe is designed to alleviate nausea, pain, constipation, and optimize skin healing. Every ingredient serves a specific post-surgery recovery purpose (i.e. flax for fiber, bone broth for absorbable amino acids, turmeric for anti-inflammatory effects). Sulinu stemmed from Bensly’s frustrations in witnessing patients being prescribed multiple vitamins to augment protein powders. This not only proved costly for the patient, but ineffective because supplement dosages were incorrect and were not paired with ingredients that helped maximize absorption. This often disrupted the patient’s gut biome and hindered healing. Sulinu makes accessing the most effective and clinically proven nutrition available while also offering: Expert Guidance from a Registered Dietitian: With Kylie Bensley at the helm, Sulinu provides access to expert guidance from a registered dietitian with a wealth of knowledge in both nutrition and the specific requirements of cosmetic surgery patients. Pre-Operative Optimization: Sulinu emphasizes the importance of pre-operative nutrition to prepare the body for surgery. Through specialized dietary recommendations, clients can enhance their resilience and support their bodies in the lead-up to their cosmetic procedures. Post-Operative Recovery Support: Sulinu's post-operative nutrition plans are designed to accelerate recovery, reduce inflammation, and promote optimal healing. These plans address the unique nutritional needs that arise after cosmetic surgery, contributing to a smoother and more comfortable recovery process. Evidence-Based Approach: Sulinu is committed to an evidence-based approach, incorporating the latest research in nutrition science to guide its recommendations. This ensures that clients receive the most up-to-date and effective nutritional support throughout their cosmetic surgery journey. * Many supplements rely solely on third-party testing, which only states the presence of the vitamin. Sulinu also uses patented ingredients to ensure effectiveness at the clinically studied amounts. Recognized as safe by FDA (GRAS-affirmed): a much harder accreditation to achieve than those of standard supplement safety. Price and Availability: All-in-One Starter Kit: $297-$347 Before + After Vitals: $97 / 20 servings (1 pouch) Pre-Op Meal Guide: $97 Post-Op Meal Plan: $197-$294 Contacts: Find us: sulinu.com Follow us: LinkedIn · IG · TikTok · Facebook: # # # PR contacts: JJBPR Tara@jjbpr.com Jennifer@jjbpr.com Contact Details JJBPR Jennifer Bickerton +1 917-968-7763 jennifer@jjbpr.com JJBPR jennifer bickerton jennifer@jjbpr.com JJBPR Tara Watnik Tara@jjbpr.com Company Website https://www.sulinu.com

December 05, 2023 10:00 AM Eastern Standard Time

YourFMO Helps Provide 3 Million Meals to Feeding America® in 2023

YourFMO

YourFMO, a national, non-governmental, independent marketing organization providing agents with valuable resources to help clients decide on Medicare options, announced that it has donated a milestone 3 million meals to Feeding America in 2023. YourFMO first partnered with Feeding America in 2019 with a shared goal: to help people get the food and resources they need to thrive. In service of this partnership, YourFMO donates the equivalent of 10 meals for every effective insurance enrollment that agents submit through the YourFMO Enrollment Center. Since the inception of this program in 2019, agent submissions via the YourFMO Enrollment Center, an essential agent resource, have grown significantly, resulting in an overall donation of the equivalent of 7.5 million meals to the Feeding America network of food banks, food pantries, and local meal programs. In 2023, YourFMO set an aggressive goal to donate the equivalent of 1 million meals. “We were thrilled to have reached 2 million meals this year, but to see us now passing the 3 million meal mark, we could not be more pleased” said Matthew Graham, senior vice president and YourFMO program leader. “We’re exceptionally grateful for the independent agents who use our enrollment center. Their support is the reason we reached this milestone in the battle against hunger.” Through its Feeding America partnership, the YourFMO team has gained new insights into the challenges faced by Americans experiencing food insecurity. Graham said the 2020 coronavirus pandemic and resulting economic downturn brought into clearer focus the important services Feeding America provides, especially within the senior population. According to Feeding America, 1 in 14 seniors, age 60 and older, was food insecure in 2021 and 7.1% of the senior population was food insecure. Every state is home to seniors and older adults who experience food insecurity. “YourFMO’s support of Feeding America has been outstanding,” said Lauren Biedron, senior vice president, Corporate Partnerships, Feeding America. “Through their generosity, they have helped to provide 7.5 million meals since 2019 to our neighbors facing hunger in the U.S. We are appreciative of YourFMO and thank them for their support." YourFMO’s support for Feeding America has inspired other efforts, including those with one of its closest partners. “The YourFMO team is relatively small, but they have motivated others across AmeriLife,” said Scotty Elliott, Chief Distribution Officer of Health for AmeriLife. “We’ve used YourFMO’s blueprint to organize other highly successful events with Feeding America throughout our company, and it’s uplifting to know that the food donations from our partners and employees have also helped so many in our community and across our nation.” YourFMO’s commitment to Feeding America will continue into the new year. “We’re so very grateful for the support from our independent agents and AmeriLife,” added Graham. “If we keep up this pace, YourFMO is certain to exceed an overall donation of 10 million meals in 2024.” Individuals wanting to support YourFMO’s efforts can visit its Team Feed Corporate donation page to make a financial contribution. ### About YourFMO YourFMO is a national non-government, independent marketing organization that is a one-stop shop for independent agents to grow their business. The site provides agents with the information they need to help their clients make thoughtful Medicare decisions. YourFMO provides agent and consumer resources, including the YourFMO Enrollment Center, which is a multi-carrier platform that allows agents to compare, quote, and enroll their clients conveniently in one place. For more information, visit YourFMO.com. About Feeding America Feeding America is committed to an America where no one is hungry. We support tens of millions of people who experience food insecurity to get the food and resources they say they need to thrive as part of a nationwide network of food banks, statewide food bank associations, food pantries and meal programs. We also invest in innovative solutions to increase equitable access to nutritious food, advocate for legislation that improves food security and work to address factors that impact food security, such as health, cost of living and employment. We partner with people experiencing food insecurity, policymakers, organizations, and supporters, united with them in a movement to end hunger. Visit FeedingAmerica.org to learn more. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Company Website https://yourfmo.com/

December 05, 2023 10:00 AM Eastern Standard Time

Classiq Unveils Comprehensive Suite of Quantum Applications on GitHub, Driving the Future of Quantum Computing Implementation

Classiq Technologies

Classiq, a pioneer in quantum computing software, today announced the launch of a comprehensive suite of quantum applications, algorithms, functions and tutorials, now publicly available in Classiq’s GitHub Repository. These algorithms and applications are all built with the Classiq platform and are open to the Classiq community. This groundbreaking release marks a significant milestone in the practical implementation of quantum computing, ensuring software advancements keep pace with the rapidly evolving quantum hardware landscape. Classiq developed the suite of new applications to empower the quantum community – as well as those investigating quantum – with an innovative approach to software development. The Classiq platform has been engineered to cater to a broad spectrum of industries, showcasing versatile applications in finance, logistics, quantum chemistry, cybersecurity and more. This extensive collection includes widely recognized quantum algorithms such as Shor, Grover and HHL, alongside a host of quantum functions critical for building robust quantum software. “Classiq’s mission is to enable building quantum programs, efficiently and at scale. This open repository places many of the common quantum programs at your fingertips,” said Amir Naveh, Chief Product Officer and co-founder of Classiq. “This provides our users the best way to learn how to build something new with Classiq. We believe this helps the quantum community build better and smarter quantum algorithms, at an accelerated pace.” At the core of Classiq’s philosophy is the belief that quantum algorithms should first be conceptualized as models. This unique approach enables the creation of optimized, hardware-aware versions of these algorithms. With the new application suite, the quantum community can easily explore and adopt this novel methodology for quantum software creation. Classiq also ensures that all resources in the GitHub repository synchronize with the latest version of the Classiq platform, providing a seamless and hassle-free experience for users. The repository is rapidly growing, with monthly additions from Classiq’s team, users and the broader community, reflecting the dynamic nature of the quantum computing field. In fact, Classiq welcomes contributions from those keen on shaping the future of quantum software. Enthusiasts are encouraged to join the collaborative effort, contribute to the growing library of applications and algorithms and engage with the community for support and feedback. All resources are accompanied by Jupyter notebooks and.qmod files, Classiq’s proprietary modeling language, ensuring easy accessibility and usability. Classiq’s commitment to education and hands-on learning is further reflected in a comprehensive library of tutorials, designed to maximize the potential of the Classiq platform. There are many ways to get involved: Participate in the Classiq Slack community Explore the capabilities of the Classiq platform Try implementing via Classiq’s GitHub Repository Classiq is at the forefront of the quantum revolution, bridging the gap between quantum hardware advancements and software development. With this comprehensive suite of quantum applications, Classiq reaffirms its commitment to fostering a vibrant, collaborative and cutting-edge quantum computing ecosystem. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing software platform (IDE, compiler and OS) with a single point of entry into quantum computing, from algorithm design to execution. Tailored to all levels of developer proficiency, Classiq aims to democratize access to quantum computing with software that equips customers to take full advantage of the quantum computing revolution. A low-code development environment that automates quantum programming ensures that a broader range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of how to program quantum computer hardware. Classiq also works closely with advanced computation hardware providers providing software for use with quantum computers, HPC and quantum simulators. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, join the Slack community, or try the Classiq platform. Contact Details Rainier Communications Michelle Allard McMahon classiqPR@rainierco.com Company Website http://www.classiq.io/

December 05, 2023 09:00 AM Eastern Standard Time

Classiq and Oxford Quantum Circuits Partner to Advance Seamless Quantum Computing and Data Center Convergence

Classiq Technologies

Classiq, a leading quantum software company, and Oxford Quantum Circuits (OQC), a pioneering quantum computing hardware company, today announced a partnership that aims to make advanced quantum computing more accessible and streamlined for users across research and industry. Classiq provides an end-to-end quantum software platform that automates the process of developing quantum software and executing it on quantum processors. The company's proprietary technology automatically synthesizes optimized quantum circuits from functional models, high-level quantum code or via Pyomo integration. OQC is focused on developing and building enterprise-ready quantum computers based on superconducting qubits. The company is committed to working with the best software partners to ensure ease of use and seamless implementation for its quantum systems. By partnering, Classiq and OQC will offer users a smooth flow including modeling, debugging, automatic quantum circuit synthesis, circuit optimization and execution on OQC's cutting-edge quantum hardware. Classiq's platform will be expanded to support executing algorithms optimized for OQC’s quantum processors, providing developers more options to select the right quantum backend for their needs, including the recently announced next-gen OQC Toshiko machine. As part of this collaboration, they will partner to further integrate their respective technologies with data centers and HPC (high-performance computing). "We’re excited to partner with OQC and help make their innovative quantum systems easily accessible to users through our software," said Nir Minerbi, CEO and co-founder of Classiq. "Together, we invite quantum developers to experience a streamlined workflow from design all the way to state-of-the-art hardware execution." "Classiq's software helps unlock the power of quantum by abstracting away complexity for developers. We are thrilled to be partnering with them to ensure our hardware can be used seamlessly by a broad quantum community to achieve real-world impact," said Ilana Wisby, CEO of OQC. This collaboration reflects both companies' commitment to advancing the quantum ecosystem by bringing together world-class quantum software and hardware. The joint solution will empower users across industries to realize the benefits of quantum computing and build the quantum future. About OQC OQC is the globally leading enterprise-ready quantum compute company. We bring quantum to our customers’ fingertips and enable them to make breakthrough discoveries. OQC Toshiko, a powerful and secure 32-qubit quantum computing platform, is now in private beta and coming soon on public cloud and data centre fabric. For more information: For more information: www.oxfordquantumcircuits.com About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing software platform (IDE, compiler and OS) with a single point of entry into quantum computing, from algorithm design to execution. Tailored to all levels of developer proficiency, Classiq aims to democratize access to quantum computing with software that equips customers to take full advantage of the quantum computing revolution. A low-code development environment that automates quantum programming ensures that a broader range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of how to program quantum computer hardware. Classiq also works closely with advanced computation hardware providers providing software for use with quantum computers, HPC and quantum simulators. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, join the Slack community, or try the Classiq platform. Contact Details Rainier Communications Michelle Allard McMahon classiqPR@rainierco.com Company Website http://www.classiq.io/

December 05, 2023 09:00 AM Eastern Standard Time

Intelligent Health Association Ushers in a New Era of Healthcare Innovation with its 2023 International Summit

1BusinessWorld

The Intelligent Health Association (IHA) proudly announces the 2023 International Summit, a landmark event scheduled from December 11 to December 15, 2023. This year's summit promises to be a transformative juncture in healthcare, blending cutting-edge technology and forward-thinking leadership in a comprehensive virtual format. In response to evolving global dynamics, the IHA has innovatively adapted the summit into a virtual conference, ensuring widespread accessibility and inclusion for health and wellness professionals worldwide. This strategic move caters to a diverse global audience, reinforcing the IHA's commitment to democratizing access to healthcare innovation. Spanning five days, the summit will address pivotal topics in healthcare technology. These include the impact of AI technologies like ChatGPT, challenges and solutions in data and cybersecurity, the evolution of remote patient monitoring and telehealth, the crucial subject of health equity, and strategies for adopting innovative technologies with effective change management. Harry P. Pappas, Founder and CEO of the Intelligent Health Association, stresses the summit's importance: "The 2023 International Summit is not just an event; it's a movement towards a technologically empowered future in healthcare. Our aim is to ignite conversations and collaborations that drive tangible improvements in patient care and healthcare delivery." Sherri Douville, CEO at Medigram and Co-Chair of the Intelligent Health Summit, adds, “We are at the cusp of a healthcare revolution, and the 2023 Summit is the catalyst. This event brings together the brightest minds in medicine, technology, and academia to redefine the contours of healthcare innovation.” Participants will have the opportunity to earn Continuing Medical Education credits (CMEs) through the prestigious Weitzman Institute, adding significant educational value to the summit. The Intelligent Health Association invites professionals from healthcare, technology, and academic sectors to be part of this groundbreaking event. Join us in shaping a future where technology and healthcare unite to enhance human health and well-being. All news and content distribution in partnership with News Direct. About the Intelligent Health Association: The Intelligent Health Association (IHA) is a global consortium of healthcare and technology leaders committed to advancing digital healthcare. Our goal is to disseminate unbiased information on innovative technologies that enhance patient care and improve clinical and business processes. The IHA champions the transformation of healthcare through high-quality educational programs and networking events, facilitating the adoption and implementation of new technologies in health and wellness ecosystems. We are dedicated to reshaping healthcare through innovation and leadership, ensuring a future where technology seamlessly integrates with patient care. Intelligent Health Association About 1BusinessWorld: 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details 1BusinessWorld Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

December 04, 2023 04:22 PM Eastern Standard Time

Image

News Release

Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA

Theralase Technologies Inc.

Theralase Technologies Inc. CEO Roger DuMoulin-White, joined Proactive's Stephen Gunnion to discuss the company's third-quarter 2023 operational highlights. The company successfully raised $1.17 million, crucial for advancing its Phase II clinical study targeting non-muscle invasive bladder cancer, particularly Bacillus Calmette-Guérin (BCG)-Unresponsive cases. The study's data shows promising superiority over FDA-approved drugs from major pharmaceutical companies, making it a groundbreaking development for Theralase. DuMoulin-White detailed the unique approach, utilizing a drug-device combination involving a light-sensitive drug instilled into the bladder. This innovative method selectively targets cancer cells, minimizing damage to healthy cells, a departure from traditional pharmacological approaches. Currently working on its pre-Breakthrough Therapy Designation (BTD) with the FDA, Theralase is aiming for formal BTD in early 2024. Dumoulin-White highlighted the company's focus on non-dilutive financing, potential partnerships, and completing the primary study treatment for around 100 patients by the end of 2024. Successful completion could lead to an FDA decision, ideally by the end of 2026, potentially accelerated with priority review. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

December 04, 2023 01:16 PM Eastern Standard Time

Video

1 ... 68 69 70 71 72 ... 299